CN116075504A - 化合物的结晶形式 - Google Patents

化合物的结晶形式 Download PDF

Info

Publication number
CN116075504A
CN116075504A CN202180044161.9A CN202180044161A CN116075504A CN 116075504 A CN116075504 A CN 116075504A CN 202180044161 A CN202180044161 A CN 202180044161A CN 116075504 A CN116075504 A CN 116075504A
Authority
CN
China
Prior art keywords
amorphous
equivalent
compound
formula
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180044161.9A
Other languages
English (en)
Inventor
朱程刚
杨铉
张朝春
徐良亮
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shenzhen Forward Pharmaceuticals Co ltd
Original Assignee
Shenzhen Forward Pharmaceuticals Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen Forward Pharmaceuticals Co ltd filed Critical Shenzhen Forward Pharmaceuticals Co ltd
Publication of CN116075504A publication Critical patent/CN116075504A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/145—Maleic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/265—Citric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

式(I)化合物的甲磺酸盐的结晶形式、盐酸盐的结晶形式和马来酸盐的结晶形式，包含所述结晶形式的药物组合物，

Description

PCT国内申请，说明书已公开。

Claims (10)

  1. PCT国内申请，权利要求书已公开。
CN202180044161.9A 2020-06-23 2021-06-23 化合物的结晶形式 Pending CN116075504A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN202010579560 2020-06-23
CN2020105795602 2020-06-23
CN2021105637622 2021-05-22
CN202110563762 2021-05-22
PCT/CN2021/101779 WO2021259316A1 (zh) 2020-06-23 2021-06-23 化合物的结晶形式

Publications (1)

Publication Number Publication Date
CN116075504A true CN116075504A (zh) 2023-05-05

Family

ID=79282005

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202180044161.9A Pending CN116075504A (zh) 2020-06-23 2021-06-23 化合物的结晶形式
CN202180029937.XA Pending CN115734968A (zh) 2020-06-23 2021-06-23 化合物的盐以及包含盐的药物组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202180029937.XA Pending CN115734968A (zh) 2020-06-23 2021-06-23 化合物的盐以及包含盐的药物组合物

Country Status (7)

Country Link
US (1) US20230234941A1 (zh)
EP (2) EP4169914A4 (zh)
JP (2) JP2023531078A (zh)
KR (2) KR20230026384A (zh)
CN (2) CN116075504A (zh)
AU (2) AU2021294553A1 (zh)
WO (2) WO2021259315A1 (zh)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102548984A (zh) * 2009-04-28 2012-07-04 安姆根有限公司 Pi3激酶和/或mtor的抑制剂
CN105461695A (zh) * 2014-09-29 2016-04-06 齐鲁制药有限公司 嘧啶或三嗪衍生物及其制备方法和用途
CN106928200A (zh) * 2015-12-30 2017-07-07 湖南福沃药业有限公司 用于治疗癌症的三嗪衍生物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6230205B2 (ja) * 2014-06-19 2017-11-15 アリアド ファーマシューティカルズ， インコーポレイテッド キナーゼ阻害のためのヘテロアリール化合物
KR20220130249A (ko) * 2016-05-26 2022-09-26 리커리엄 아이피 홀딩스, 엘엘씨 Egfr 억제제 화합물
CN108864079B (zh) * 2017-05-15 2021-04-09 深圳福沃药业有限公司 一种三嗪化合物及其药学上可接受的盐
CN111747950B (zh) * 2019-03-29 2024-01-23 深圳福沃药业有限公司 用于治疗癌症的嘧啶衍生物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102548984A (zh) * 2009-04-28 2012-07-04 安姆根有限公司 Pi3激酶和/或mtor的抑制剂
CN105461695A (zh) * 2014-09-29 2016-04-06 齐鲁制药有限公司 嘧啶或三嗪衍生物及其制备方法和用途
CN106928200A (zh) * 2015-12-30 2017-07-07 湖南福沃药业有限公司 用于治疗癌症的三嗪衍生物

Also Published As

Publication number Publication date
AU2021294553A1 (en) 2022-09-22
EP4169915A1 (en) 2023-04-26
EP4169914A4 (en) 2024-07-24
CN115734968A (zh) 2023-03-03
JP2023531077A (ja) 2023-07-20
EP4169915A4 (en) 2024-09-04
JP2023531078A (ja) 2023-07-20
EP4169914A1 (en) 2023-04-26
WO2021259315A1 (zh) 2021-12-30
WO2021259316A1 (zh) 2021-12-30
AU2021294796A1 (en) 2022-09-22
KR20230026383A (ko) 2023-02-24
US20230234941A1 (en) 2023-07-27
KR20230026384A (ko) 2023-02-24

Similar Documents

Publication Publication Date Title
JP6676602B2 (ja) 上皮成長因子受容体キナーゼ阻害剤の塩
KR102354963B1 (ko) N-｛4-[(6,7-다이메톡시퀴놀린-4-일)옥시]페닐｝-n'-(4-플루오로페닐) 사이클로프로판-1,1-다이카복스아마이드의 결정질 고체 형태, 제조 방법 및 사용 방법
US10550101B2 (en) Crystalline forms of mesylate salt of pyridinyl amino pyrimidine derivative, preparation methods therefor, and applications thereof
WO2014173291A1 (zh) 氘代的二氨基嘧啶化合物以及包含该化合物的药物组合物
CN110678455B (zh) 3-苯基-4-丙基-1-(吡啶-2-基)-1h-吡唑-5-醇盐酸盐的新颖结晶型固体化合物
CN112105616B (zh) 药学化合物、其盐类、其制剂和其制备和使用方法
CN113840604A (zh) Jak2抑制剂的结晶形式
US20230174554A1 (en) Solid form of macrocyclic compound, preparation therefor and use thereof
CN115916791A (zh) 结晶ret抑制剂
JP2016518408A (ja) 上皮増殖因子受容体キナーゼ阻害剤の塩
EP3941472B1 (en) Crystalline and amorphous forms of-(5-((4-ethylpiperazin-1-yl)methyl)pyridine-2-yl)-5-fluoro-4-(3-isopropyl-2-methyl-2 <ns1:i>h</ns1:i>?-indazol-5-yl)pyrimidin-2-amine and its salts, and preparation methods and therapeutic uses thereof
CN116075504A (zh) 化合物的结晶形式
CN115413277B (zh) 吡嗪取代的烟酰胺的固体形式及其制备和用途
US20240317746A1 (en) Crystalline forms of an azetidine parp1 inhibitor
US20240174669A1 (en) Crystalline forms of a parp1 inhibitor
CN107868059B (zh) 一种喹唑啉衍生物的盐、其制备方法及应用
WO2023116895A1 (zh) Kras抑制剂的多晶型物及其制备方法和用途
US20230183266A1 (en) Crystalline forms of ret inhibitor and preparation thereof
WO2022224269A1 (en) Co-crystals, salts and solid forms of niraparib
AU2023206373A1 (en) Crystalline forms of 3-(5-(2-hydroxy-2-methylpropoxy)-6-methylpyrazin-2-yl)-1h-indole-7-carbonitrile

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination